Table 3 Differences of HCV-monoinfected and HIV/HCV coinfected patients with a baseline liver stiffness > 9.5 kPa in function of the achievement of a liver stiffness < 9.5 kPa, measured at 12 months after starting DAAs.

From: Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs

Characteristic

Patients with M12 liver stiffness ≤ 9.5 kPa (n = 16)

Patients with M12 liver stiffness > 9.5 kPa (n = 40)

p univariant

Exp (B) (CI 95%)

p multivariant

Male sex [n (%)]

11 (69)

34 (85)

0.263

  

Age (years), median (IQR)

54 (50–58)

55 (51–60)

0.473

  

PWID

4 (25)

22 (55)

0.074

  

HIV/HCV coinfection [n (%)]

5 (56)

35 (75)

0.259

  

HCV genotype [n (%)]

  

0.368

  

1a

6 (38)

12 (30)

   

1b

6 (38)

14 (35)

   

3

2 (12)

5 (13)

   

4

1 (6)

9 (23)

   

Mixed 1a + 1b

1 (6)

0 (0)

   

Excessive alcohol consumption [n (%)]

1 (6)

3 (7)

0.592

  

Treatment-experienced [n (%)]

16 (32)

8 (36)

0.789

  

Baseline HCV viral load (log UI/l), median (IQR)

6.3 (4.8–6.8)

5.9 (5.0–6.4)

0.384

  

Baseline fibrosis stage [n (%)]

  

0.003

  

Significant fibrosis (F2–F3)

12 (75)

12 (30)

   

Cirrhosis (F4)

4 (25)

28 (70)

   

Baseline liver stiffness, median (IQR)

11.6 (10.3–16.8)

20.1 (13.2–32.9)

0.002

0.887 (0.793–0.992)

0.036

Percentual change of liver stiffness after DAAs (%), median (IQR)

− 46 (− 61, − 41)

5 (− 37, + 18)

 < 0.001

  

Baseline APRI, median (IQR)

1.00 (0.42–2.06)

1.35 (0.71–2.97)

0.108

  

Percentual change of APRI after DAAs (%), median (IQR)

− 44 (− 71, − 38)

− 55 (− 65, − 30)

0.955

  

Baseline FIB-4, median (IQR)

1.76 (1.32–4.91)

3.33 (1.80–7.89)

0.054

  

Percentual change of FIB-4 after DAAs (%), median (IQR)

− 7 (− 35, + 15)

− 27 (− 44, 0)

0.257

  

Platelets/mm3 × 1000, median (IQR)

202 (137–232)

114 (78–169)

0.005

  

Baseline CXCL4 concentration (ng/ml), median (IQR)

3421 (2109–7199)

2239 (1284–5413)

0.381

  

Percentual change of CXCL4 levels after DAAs (%), median (IQR)

7 (− 25, + 75)

1 (− 46, + 89)

0.914

  

Baseline TGF-β1 concentration (pg/ml), median (IQR)

20,343 (8599–30,588)

11,778 (7855–22,045)

0.103

  

Percentual change of TGF-β1 levels after DAAs (%), median (IQR)

− 2 (− 38, + 59)

− 14 (− 32, + 74)

0.842

  

Baseline HGF concentration (pg/ml)

4324 (2960–5686)

6088 (3780–11,031)

0.019

  

Percentual change of HGF levels after DAAs (%), median (IQR)

− 5 (− 39, + 8)

− 20 (− 44, + 8)

0.677

  
  1. HCV hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range, PWID people who inject drugs, DAA directed antiviral (anti-HCV) agents, APRI AST to Platelet Ratio Index, FIB-4 Fibrosis-4 score, CXCL4 chemokine (C-X-C motif) ligand 4, TGF-β1 transforming growth factor β1, HGF hepatocyte growth factor.
Back to article page